Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Illumina Inc. is another one of the best cancer stocks on our list.

TheFly reported on January 7 that TD Cowen raised its price target on ILMN to $140 from $115 while maintaining a Hold rating. The change was included in the company’s outlook for the life science tools industry for the fourth quarter. Although several firms have already released cautious advice for 2026, the analyst pointed out that recent share price advances have elevated expectations. TD Cowen feels this leaves space for upside next year.

Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside

Separately, on January 6, Illumina Inc. (NASDAQ:ILMN) launched Illumina Connected Multiomics, a cloud-based platform designed to integrate and analyze large multiomic datasets.

Illumina Inc. (NASDAQ:ILMN) develops advanced genomic sequencing and multiomics solutions, enabling precision oncology research, biomarker discovery, and targeted therapies. Its AI-driven platforms accelerate cancer diagnostics, drug development, and personalized treatment strategies, positioning the company as a leader in oncology-focused genomic innovation.

While we acknowledge the risk and potential of ILMN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ILMN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.